单剂与低剂量利妥昔单抗治疗糖皮质激素抵抗或复发免疫性血小板减少症的多中心随机对照研究
这项前瞻性、多中心、开放标签、随机对照试验将糖皮质激素抵抗或复发的免疫性血小板减少症患者按1:1随机分为重复低剂量组(利妥昔单抗100 mg每周1次,共4周)和单剂组(375 mg/m²)。两组总体缓解率分别为64.3%与67.4%(p=.759),完全缓解率分别为23.8%与28.3%(p=.635);单剂组在心理状态、生活质量、社会活动和工作方面优于低剂量组,并显著减少就诊次数而不影响疗效。
要点
- 低剂量组与单剂组总体缓解率64.3%对67.4%(p=.759)、完全缓解率23.8%对28.3%(p=.635)。
- 单剂组较低剂量组改善患者心理状态、生活质量、社会活动和工作。
- 单剂组显著减少就诊次数且不损害疗效。
核心结论
- 单剂利妥昔单抗治疗糖皮质激素抵抗或复发免疫性血小板减少症在有效性和安全性上与重复低剂量相当。
- 单剂方案优化医疗资源利用、提高利妥昔单抗的成本效益,是可能替代低剂量方案的更方便选择。
研究设计与样本
- 前瞻性、多中心、开放标签、随机对照试验,比较两种利妥昔单抗剂量方案治疗糖皮质激素抵抗或复发免疫性血小板减少症。
- 患者按1:1随机分配至重复低剂量组(100 mg每周1次,共4周)或单剂组(375 mg/m²)。
- 研究已完成,在ClinicalTrials.gov注册,注册号NCT03258866。
主要发现
- 总体缓解:低剂量组64.3%对单剂组67.4%(p=.759)。
- 完全缓解:低剂量组23.8%对单剂组28.3%(p=.635)。
- 健康相关生活质量方面,单剂组较低剂量组改善患者心理状态、生活质量、社会活动和工作。
- 单剂组显著减少就诊次数且不损害疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder, in which rituximab (RTX) induces the best long-term effect among recommended second-line treatments. Nevertheless, the optimal regimen of RTX remains unclear. We herein conducted a prospective, multicenter, open-label, randomized controlled trial to compare the efficacy and safety of RTX at two different dosage regimens in patients with corticosteroid-resistant or relapsed ITP. Recruited patients were randomly assigned (1:1) to receive either RTX at a repeated low dose (100 mg weekly for 4 weeks, LD-RTX) or at a single dose (375 mg/m2 , S-RTX). Overall response was achieved in 64.3% of patients who received LD-RTX versus 67.4% of those receiving S-RTX (p = .759). The complete response (CR) rate was 23.8% after LD-RTX and 28.3% after S-RTX (p = .635). In health-related quality of life, S-RTX improved patients' psychological status, quality of life, social activities, and work compared with LD-RTX. Furthermore, S-RTX significantly reduced physician visits without compromising efficacy. Our findings demonstrate that a S-RTX is comparable to LD-RTX in effectiveness and safety for treatment of corticosteroid-resistant or relapsed ITP. The single-dosage regimen optimizes the use of medical resources, improves the cost-effectiveness of RTX, and represents a promising and more convenient replacement for LD-RTX in ITP. This study has been completed and is registered with ClinicalTrials.gov, number NCT03258866.
引用
- Ni X, Li D, Yuan C, et al. Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: A multicenter, randomized, controlled study. Am J Hematol. 2022. PMID: 35049070. doi:10.1002/ajh.26473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。